MNMD Mind Medicine (MindMed) Inc.
USHealthcareAs of 2026-04-02 15:59
Why MNMD matters now
Mind Medicine (MindMed) Inc. (MNMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $20.69 with +0.44% on the session and $1.56B in market capitalization; recent performance reads 1-month +0.05% and YTD +54.52%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-77.1M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.4%.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
9.55
P/S
0.00
EV/EBITDA
-10.83
DCF Value
$2.84
FCF Yield
-5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-102.5%
ROA
-59.2%
ROIC
-60.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-77.1M | $-0.71 |
| Q4 2025 | $0.00 | $-50.4M | $-0.50 |
| FY 2025 | $0.00 | $-183.8M | $-2.06 |
| Q3 2025 | $0.00 | $-67.3M | $-0.78 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$20.00
Target (Median)
$20.00
Target Range
$14.00 - $28.00
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
2.62
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.